New periodic paralysis drug has rochester roots

(University of Rochester Medical Center) More than 15 years of research led by neurologists at the University of Rochester Medical Centerhas culminated in the first approved treatment for individuals with a rare neuromuscular disorder called periodic paralysis. The US Food and Drug Administration recently approved dichlorphenamide, which is being marketed under the brand name Keveyis by Taro Pharmaceuticals, for individuals with the disease.